The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.
CHEYENNE, Wyo., Dec. 1, 2017 /PRNewswire/ — Xynomic Pharma, a clinical stage US oncology drug development company, today announced that it will initiate a Ph 1/2 trial, in collaboration with Janssen R&D, LLC (Janssen Pharmaceutical Companies of Johnson & Johnson, hereafter Janssen) and Memorial Sloan Kettering Cancer Center (MSK), to combine Abexinostat with Ibrutinib against r/r DLBCL Details
CHEYENNE, Wyo., Oct. 30, 2017 /PRNewswire/ — Xynomic Pharma, a clinical stage US oncology drug development company, today announced that it has acquired exclusive global rights to develop, manufacture and commercialize BI 882370, a 2nd-generation RAF inhibitor, from Boehringer Ingelheim, a top-20 global pharmaceutical company. Under the terms of the agreement Xynomic will pay upfront, milestone and Details
Mr. Y. Mark Xu, Chairman, CEO and President, has been invited to speak at this high profile conference. Other presenting companies include Roche, Sanofi, Hengrui and Sino Biopharm. The venue is Mandarin Oriental Hotel, Hong Kong. This conference is expected to draw attendance of over 100 leading Asian institutional investors and high net worth individuals.
CHEYENNE, Wyo., May 22, 2017 /PRNewswire/ — Xynomic Pharma, a clinical stage US oncology drug R&D company, today announced that it has entered into a strategic partnership with the University of California San Francisco (“UCSF”) to conduct PAX Study, a multi-national, multi-center, randomized Phase 2/3 study of Pazopanib plus Abexinostat versus Pazopanib monotherapy in patients with locally Details
Sponsored by NCI and UCSF 51 patients (72% had received two or more lines of therapy in the locally advanced or metastatic setting), Phase 1b, open-label, dose-escalation/expansion trial of Abexinostat in combination with GSK’s pazopanib Abexinostat well tolerated in combination with pazopanib First ever clinical trial to test the hypothesis that epigenetic modiﬁcation with HDAC Details
March. 8, 2017 — Xynomic Pharmaceuticals, Inc., a US-China oncology startup, has acquired Greater China rights to a novel ACAT-1 inhibitor for cancer indications from Resarci Therapeutics of West Lafayette, Indiana. It will be tested as a treatment for prostate, pancreatic and other solid tumors. Xynomic will pay $1.2 million in upfront and milestone payments, Details
CHEYENNE, Wyoming, Feb. 24, 2017 /PRNewswire/ — Xynomic Pharmaceuticals, Inc., an oncology drug research and development company, today announced that it has acquired exclusive worldwide rights to develop, manufacture and commercialize Abexinostat, a potentially best-in-class innovative HDAC inhibitor targeting hematological and solid tumors. To date a total of 17 Phase 1 and 2 clinical trials Details